These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

229 related articles for article (PubMed ID: 34073316)

  • 1.
    Nasrollahzadeh D; Roshandel G; Delhomme TM; Avogbe PH; Foll M; Saidi F; Poustchi H; Sotoudeh M; Malekzadeh R; Brennan P; Mckay J; Hainaut P; Abedi-Ardekani B
    Int J Mol Sci; 2021 May; 22(11):. PubMed ID: 34073316
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Somatic mutations in plasma cell-free DNA are diagnostic markers for esophageal squamous cell carcinoma recurrence.
    Ueda M; Iguchi T; Masuda T; Nakahara Y; Hirata H; Uchi R; Niida A; Momose K; Sakimura S; Chiba K; Eguchi H; Ito S; Sugimachi K; Yamasaki M; Suzuki Y; Miyano S; Doki Y; Mori M; Mimori K
    Oncotarget; 2016 Sep; 7(38):62280-62291. PubMed ID: 27556701
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Targeted sequencing of circulating cell-free DNA in stage II-III resectable oesophageal squamous cell carcinoma patients.
    Meng P; Wei J; Geng Y; Chen S; Terpstra MM; Huang Q; Zhang Q; Su Z; Yu W; Su M; Kok K; van den Berg A; Gu J
    BMC Cancer; 2019 Aug; 19(1):818. PubMed ID: 31429737
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Multi-region sequencing reveals genetic correlation between esophageal squamous cell carcinoma and matched cell-free DNA.
    Yuan Z; Wang X; Geng X; Li Y; Tan F; Xue Q; Gao S; He J
    Cancer Genet; 2021 Nov; 258-259():93-100. PubMed ID: 34688997
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Molecular Barcode Sequencing for Highly Sensitive Detection of Circulating Tumor DNA in Patients with Esophageal Squamous Cell Carcinoma.
    Hagi T; Kurokawa Y; Takahashi T; Saito T; Yamashita K; Tanaka K; Makino T; Yamasaki M; Nakajima K; Mori M; Doki Y
    Oncology; 2020; 98(4):222-229. PubMed ID: 31846968
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A pilot study of ultra-deep targeted sequencing of plasma DNA identifies driver mutations in hepatocellular carcinoma.
    Labgaa I; Villacorta-Martin C; D'Avola D; Craig AJ; von Felden J; Martins-Filho SN; Sia D; Stueck A; Ward SC; Fiel MI; Mahajan M; Tabrizian P; Thung SN; Ang C; Friedman SL; Llovet JM; Schwartz M; Villanueva A
    Oncogene; 2018 Jul; 37(27):3740-3752. PubMed ID: 29628508
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Detection of cancer specific mutations in early-stage non-small cell lung cancer using cell-free DNA by targeted sequencing.
    He Y; Zhang X; Wang L; Tian Z; Liu Q; Yao J; Liu Y; Li C; Min L; Shan B
    Int J Oncol; 2016 Dec; 49(6):2351-2358. PubMed ID: 27748796
    [TBL] [Abstract][Full Text] [Related]  

  • 8.
    Vitale SR; Groenendijk FH; van Marion R; Beaufort CM; Helmijr JC; Dubbink HJ; Dinjens WNM; Ewing-Graham PC; Smolders R; van Doorn HC; Boere IA; Berns EMJJ; Helleman J; Jansen MPHM
    Biomolecules; 2020 Mar; 10(3):. PubMed ID: 32156073
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ultra-Sensitive Mutation Detection and Genome-Wide DNA Copy Number Reconstruction by Error-Corrected Circulating Tumor DNA Sequencing.
    Mansukhani S; Barber LJ; Kleftogiannis D; Moorcraft SY; Davidson M; Woolston A; Proszek PZ; Griffiths B; Fenwick K; Herman B; Matthews N; O'Leary B; Hulkki S; Gonzalez De Castro D; Patel A; Wotherspoon A; Okachi A; Rana I; Begum R; Davies MN; Powles T; von Loga K; Hubank M; Turner N; Watkins D; Chau I; Cunningham D; Lise S; Starling N; Gerlinger M
    Clin Chem; 2018 Nov; 64(11):1626-1635. PubMed ID: 30150316
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Genetic profiling using plasma-derived cell-free DNA in therapy-naïve hepatocellular carcinoma patients: a pilot study.
    Ng CKY; Di Costanzo GG; Tosti N; Paradiso V; Coto-Llerena M; Roscigno G; Perrina V; Quintavalle C; Boldanova T; Wieland S; Marino-Marsilia G; Lanzafame M; Quagliata L; Condorelli G; Matter MS; Tortora R; Heim MH; Terracciano LM; Piscuoglio S
    Ann Oncol; 2018 May; 29(5):1286-1291. PubMed ID: 29509837
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Development and validation of predictive models for esophageal squamous cell carcinoma and its precancerous lesions using terminal motif analysis in circulating cell-free DNA].
    Liu SY; Li ZQ; Dou LZ; Zhang YM; Liu Y; Liu YM; Ke Y; Liu XD; Wu HR; Chu JT; He S; Wang GQ
    Zhonghua Zhong Liu Za Zhi; 2024 Jun; 46(6):549-565. PubMed ID: 38880735
    [No Abstract]   [Full Text] [Related]  

  • 12. Circulating Cell-Free DNA Levels Could Predict Oncological Outcomes of Patients Undergoing Esophagectomy for Esophageal Squamous Cell Carcinoma.
    Hsieh CC; Hsu HS; Chang SC; Chen YJ
    Int J Mol Sci; 2016 Dec; 17(12):. PubMed ID: 27999323
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Plasma cell-free tumor DNA, PIK3CA and TP53 mutations predicted inferior endocrine-based treatment outcome in endocrine receptor-positive metastatic breast cancer.
    Chen TW; Hsiao W; Dai MS; Lin CH; Chang DY; Chen IC; Wang MY; Chang SH; Huang SM; Cheng AL; Wu KW; Tan KT; Lu YS
    Breast Cancer Res Treat; 2023 Oct; 201(3):377-385. PubMed ID: 37344660
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Targeted sequencing reveals TP53 as a potential diagnostic biomarker in the post-treatment surveillance of head and neck cancer.
    van Ginkel JH; de Leng WW; de Bree R; van Es RJ; Willems SM
    Oncotarget; 2016 Sep; 7(38):61575-61586. PubMed ID: 27528217
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical significance of gene mutation in ctDNA analysis for hormone receptor-positive metastatic breast cancer.
    Shibayama T; Low SK; Ono M; Kobayashi T; Kobayashi K; Fukada I; Ito Y; Ueno T; Ohno S; Nakamura Y; Takahashi S
    Breast Cancer Res Treat; 2020 Apr; 180(2):331-341. PubMed ID: 32020432
    [TBL] [Abstract][Full Text] [Related]  

  • 16. TP53 Mutations in Esophageal Squamous Cell Carcinoma.
    Zhong L; Li H; Chang W; Ao Y; Wen Z; Chen Y
    Front Biosci (Landmark Ed); 2023 Sep; 28(9):219. PubMed ID: 37796679
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical Utility of Circulating Cell-Free DNA Mutations in Anaplastic Thyroid Carcinoma.
    Qin Y; Wang JR; Wang Y; Iyer P; Cote GJ; Busaidy NL; Dadu R; Zafereo M; Williams MD; Ferrarotto R; Gunn GB; Wei P; Patel K; Hofmann MC; Cabanillas ME
    Thyroid; 2021 Aug; 31(8):1235-1243. PubMed ID: 33599171
    [No Abstract]   [Full Text] [Related]  

  • 18. Transcriptionally Active Human Papillomavirus Infection in a Minority of Esophageal Squamous Cell Carcinomas in North America.
    Bauer AH; Alkhateeb KJ; Agoston AT; Odze RD; Joshi MG; Huffman BM; Enzinger P; Perez K; Deshpande V; Cleary JM; Wee JO; Dong F; Zhao L
    Am J Surg Pathol; 2024 Jul; 48(7):883-889. PubMed ID: 38726899
    [TBL] [Abstract][Full Text] [Related]  

  • 19. TP53 mutations in circulating free DNA from Egyptian patients with non-Hodgkin's lymphoma.
    Hosny G; Farahat N; Hainaut P
    Cancer Lett; 2009 Mar; 275(2):234-9. PubMed ID: 19046801
    [TBL] [Abstract][Full Text] [Related]  

  • 20. An Old Story Retold: Loss of G1 Control Defines A Distinct Genomic Subtype of Esophageal Squamous Cell Carcinoma.
    Wang Q; Bai J; Abliz A; Liu Y; Gong K; Li J; Shi W; Pan Y; Liu F; Lai S; Yang H; Lu C; Zhang L; Chen W; Xu R; Cai H; Ke Y; Zeng C
    Genomics Proteomics Bioinformatics; 2015 Aug; 13(4):258-70. PubMed ID: 26386145
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.